ArticleInflammatory bowel diseases2024

Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.

Xiaoyan Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.